ClinicaliQ Trial Snapshot
- Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN — Recruiting • Phase III • NCT03955445.
- Sponsor: Novartis Pharmaceuticals.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
Eligibility Snapshot
- : - Patients must have completed the treatment period of the CLNP023X2202, CLNP023B12301 or CLNP023B12302 study on study drug
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.